Get the Stockscreener App
12.43
5.63%
0.71
Candel Therapeutics Inc stock is traded at $12.43, with a volume of 1.74M.
It is up +5.63% in the last 24 hours and up +21.61% over the past month.
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
See More
Previous Close:
$11.72
Open:
$11.49
24h Volume:
1.74M
Relative Volume:
1.00
Market Cap:
$950.36M
Revenue:
$31,000
Net Income/Loss:
$-54.42M
P/E Ratio:
-12.71
EPS:
-0.9778
Net Cash Flow:
$-48.99M
1W Performance:
+17.90%
1M Performance:
+21.61%
6M Performance:
+119.88%
1Y Performance:
+103.28%
1-Day Range:
$11.11
$12.48
1-Week Range:
$10.41
$12.48
52-Week Range:
$4.35
$12.48
Candel Therapeutics Inc Stock (CADL) Company Profile
Name
Candel Therapeutics Inc
Sector
Industry
Phone
617-916-5445
Address
117 KENDRICK STREET, NEEDHAM
Compare CADL vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CADL
Candel Therapeutics Inc
|
12.42 | 896.80M | 31,000 | -54.42M | -48.99M | -0.9778 |
VRTX
Vertex Pharmaceuticals Inc
|
515.73 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
807.26 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
990.59 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
212.75 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.20 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-20-26 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-28-25 | Initiated | Stephens | Overweight |
| Sep-03-25 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-30-25 | Resumed | H.C. Wainwright | Buy |
| Feb-20-25 | Initiated | Citigroup | Buy |
| Feb-19-25 | Initiated | Canaccord Genuity | Buy |
| Feb-07-25 | Initiated | BofA Securities | Buy |
| Dec-02-22 | Initiated | H.C. Wainwright | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Aug-23-21 | Initiated | Credit Suisse | Outperform |
| Aug-23-21 | Initiated | Jefferies | Buy |
| Aug-23-21 | Initiated | UBS | Buy |
View All
Candel Therapeutics Inc Stock (CADL) Latest News
Freedom Broker raises Candel Therapeutics stock price target on trial progress - Investing.com Canada
Weekly Recap: CAN-2409 BLA filing, 2027 U.S. launch target and Q2 widened loss, shares up - TradingView
Research Analysts Set Expectations for CADL Q3 Earnings - marketbeat.com
CADL Q3 EPS Estimate Reduced by Brookline Capital Markets - marketbeat.com
(CADL) Risk Channels and Responsive Allocation - Stock Traders Daily
Candel Therapeutics (NASDAQ:CADL) Lowered to Sell Rating by Wall Street Zen - marketbeat.com
Candel Therapeutics Reported Better-Than-Feared Q1 Loss – But All Eyes Turn To This Pivotal Event Tomorrow - Stocktwits
Candel Therapeutics, Inc. (NASDAQ:CADL) Given Consensus Recommendation of "Moderate Buy" by Brokerages - marketbeat.com
CADL Stock On Track For Best Day In Nearly 16 Months — What’s Driving The Rally? - Stocktwits
Candel Therapeutics (NASDAQ:CADL) Stock Price Expected to Rise, Bank of America Analyst Says - marketbeat.com
LifeSci Capital Maintains Candel Therapeutics(CADL.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Candel Therapeutics (NASDAQ:CADL) Stock Price Down 4.6% After Earnings Miss - marketbeat.com
Candel Therapeutics, Inc. Stock 12‑Month Price Target Raised to $20.88, Implies 77% Upside - TradingView
BofA Adjusts Price Target on Candel Therapeutics to $12 From $9 - Moomoo
Equities Analysts Offer Predictions for CADL FY2028 Earnings - marketbeat.com
Biotech Stocks At 52-Week HighsPARK +10%, AVAH +24%, CADL +10% On Q2 Reports, LH, COAG - RTTNews
A Quick Look at Today's Ratings for Candel Therapeutics(CADL.US), With a Forecast Between $12 to $23 - Moomoo
Candel Therapeutics (NASDAQ:CADL) Releases Earnings Results, Misses Expectations By $0.30 EPS - marketbeat.com
CADL Rises As Biotech Eyes First Commercial Product in 2027 — CEO Points To ‘Meaningful Execution’ Toward BLA Submission In Q4 - TradingView
Candel Therapeutics (NASDAQ:CADL) Sets New 12-Month HighHere's What Happened - marketbeat.com
HC Wainwright Reaffirms Buy Rating for Candel Therapeutics (NASDAQ:CADL) - marketbeat.com
Candel Therapeutics Q2 EPS of $(0.52) misses estimates - scanx.trade
Candel Therapeutics Reports Q2 2026 Financials and Pipeline Progress in SEC Form 10-Q - Kalkine Media
Candel Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
This Small-Cap Biotech Is Having Its Best Week In A Month – Here’s What’s Driving It - Stocktwits
Form 8K Candel Therapeutics Inc For: 13 August By Investing.com - Investing.com Canada
Candel Therapeutics Q2 Loss Widens - marketscreener.com
Earnings Flash (CADL) Candel Therapeutics Posts Q2 Net Loss $0.52 a Share, vs. FactSet Est of $0.21 Loss - marketscreener.com
Candel Therapeutics, Inc. Q2 2026: Net income $(38.9M), EPS $(0.52) — 10-Q Summary - TradingView
Candel Therapeutics (NASDAQ: CADL) widens H1 2026 loss while boosting cash above $200M - Stock Titan
Candel Therapeutics reports Q2 2026 net loss $38.9M, cash $201.6M; plans BLA submission Q4 2026 - TradingView
Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights - The Manila Times
Candel's Prostate Therapy Candidate Shows 39% Disease-Free Survival Improvement - Stock Titan
CADL Stock Edges Up After Hours On Strong Extended Prostate Cancer Data - Stocktwits
Candel Therapeutics at canaccord growth conference: prostate cancer push By Investing.com - Investing.com Canada
Candel Therapeutics Eyes 2026 Prostate Cancer Filing as Lung Study Ramps Up - marketbeat.com
Candel Therapeutics at canaccord growth conference: prostate cancer push - Investing.com
Why CADL Stock Plunged Nearly 15% In After-Hours Trading Today - Stocktwits
Candel Therapeutics (CADL) Holds Near $10.56 as Biotech Stock Tests Key ResistanceChaikin Flow - dars.gov.et
Janus Henderson Group PLC Makes New Investment in Candel Therapeutics, Inc. $CADL - marketbeat.com
Candel Therapeutics (CADL) Short Interest & Short Float | Updated Aug 2026 - marketbeat.com
Candel Therapeutics Inc expected to post a loss of 24 cents a shareEarnings Preview - TradingView
Candel Therapeutics Inc (CADL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Wall Street Zen Upgrades Candel Therapeutics (NASDAQ:CADL) to "Hold" - marketbeat.com
Candel Therapeutics Inc (CADL) Stock News Today - TradingKey
Candel Therapeutics: Getting Closer, And Building Out More Paths (NASDAQ:CADL) - Seeking Alpha
(CADL) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Candel Therapeutics (CADL) Expected to Announce Earnings on Thursday - MarketBeat
Candel Therapeutics Insider Ups Holding By 14% During Year - Moomoo
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Candel Therapeutics to present prostate cancer data at ASTRO - Investing.com
Candel Therapeutics Inc Stock (CADL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Candel Therapeutics Inc Stock (CADL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Tyagarajan Seshu | Chief Technology Officer |
Jun 29 '26 |
Sale |
10.02 |
7,000 |
70,151 |
83,865 |
2.24%
1.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):